Anti-Obesity Drug Development

"Anti-Obesity Drug Development: Physiology, Pharmacology and Drug Delivery" is a complete reference for pharmaceutical researchers in this key area of research and clinical development. The contents of the book are organized in four parts. The first provides an overview of the foundations and historical development of anti-obesity drugs, including extensive discussion of comorbidities and how they impact drug activity and efficacy. Part two is dedicated to the drug targets involved in the progression of obesity treatment. These include GLPRI and GIPR agonists, Incretin/Glucagon, RM-493 and Liraglutide, Pramlintide and metreleptin, Growth Hormone, FXR and GPR131, and the Gut Microbiota. Part three discusses the most common drugs available in the market and their pharmacological parameters. The final part of the book covers all natural products known to have scientific evidence on the treatment of obesity. "Anti-Obesity Drug Development: Physiology, Pharmacology and Drug Delivery" is the perfect reference for pharmacology researchers and those involved in new drug development both in academic and corporate environments. Research-physicians, endocrinologists, and nutritionists will also benefit from the comprehensive overview of treatments covered in this book.